Lars Lindén

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

Sven Golfier, Charlotte Kopitz, Antje Kahnert et al. · Molecular Cancer Therapeutics · 2014 · 245 citations

The Crystal Structures of <i>Zea mays</i> and Arabidopsis 4-Hydroxyphenylpyruvate Dioxygenase

Iris M. Fritze, Lars Lindén, Jörg Freigang et al. · PLANT PHYSIOLOGY · 2004 · 109 citations · Full text

Generation and Comparative Characterization of Glycosylated and Aglycosylated Human IgG1 Antibodies

Dmitrij Hristodorov, Rainer Fischer, Hannah Joerissen et al. · Molecular Biotechnology · 2012 · 73 citations

Glycoproteomics, Autoimmune Disease, Allergy +12

Synergistic Effect of a Mesothelin-Targeted ²²⁷Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models

Katrine Wickstroem, Urs B. Hagemann, Véronique Cruciani et al. · Journal of Nuclear Medicine · 2019 · 51 citations · Full text

Molecular Biology, Immunotherapeutics, Tumor Biology +17

Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer

Jörg Willuda, Lars Lindén, Hans‐Georg Lerchen et al. · Molecular Cancer Therapeutics · 2017 · 45 citations